Previous Article | Next Article ![]()
Journal of Virology, June 2006, p. 5125-5134, Vol. 80, No. 11
0022-538X/06/$08.00+0 doi:10.1128/JVI.02674-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Mikiko Kanamori-Koyama,3,4,
Ken Sugimoto,1,3
Takeshi Sairenji,5
Yukihiro Nishiyama,3 and
Yasushi Kawaguchi1,2,3,4*
Division of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639,1 PRESTO, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012,2 Department of Virology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya 466-8550,3 Department of Cell Regulation, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510,4 Division of Biosignaling, Department of Biomedical Science, School of Life Science, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan5
Received 21 December 2005/ Accepted 14 March 2006
Epstein-Barr virus (EBV) BGLF4 is a viral protein kinase that is expressed in the lytic phase of infection and is packaged in virions. We report here that BGLF4 is a tegument protein that dissociates from the virion in a phosphorylation-dependent process. We also present evidence that BGLF4 interacts with and phosphorylates BZLF1, a key viral regulator of lytic infection. These conclusions are based on the following observations. (i) In in vitro tegument release assays, a significant fraction of BGLF4 was released from virions in the presence of physiological NaCl concentrations. (ii) Addition of physiological concentrations of ATP and MgCl2 to virions enhanced BGLF4 release, but phosphatase treatment of virions significantly reduced BGLF4 release. (iii) A recombinant protein containing a domain of BZLF1 was specifically phosphorylated by purified recombinant BGLF4 in vitro, and BGLF4 altered BZLF1 posttranslational modification in vivo. (iv) BZLF1 was specifically coimmunoprecipitated with BGLF4 in 12-O-tetradecanoylphorbol-13-acetate-treated B95-8 cells and in COS-1 cells transiently expressing both of these viral proteins. (v) BGLF4 and BZLF1 were colocalized in intranuclear globular structures, resembling the viral replication compartment, in Akata cells treated with anti-human immunoglobulin G. Our results suggest that BGLF4 functions not only in lytically infected cells by phosphorylating viral and cellular targets but also immediately after viral penetration like other herpesvirus tegument proteins.
Present address: Department of Veterinary Microbiology, Graduate School of Agricultural and Life Science, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Present address: Global Drug Discovery, Discovery Research Laboratories, Shionogi & Co. Ltd., 2-5-1, Settsu-shi, Mishima, Osaka 566-0022, Japan.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|